new begin upgrad
multi-mod platform catalyz market share
momentum risk execut
new strateg vision remain pend
commit manag board get right
clear pt
stori chang last juli downgrad given slower
commerci traction clinic catalyst void less differenti vs
competit product senza spinal cord stimul devic
implant devic treat chronic pain neuromodul
dilig continu indic senza high-frequ hf therapi
drive less differenti result impli landmark senza-rct
studi year ago new platform disclos nan
manag chang announc yesterday repres materi chang
strategi evid board commit execut
sharehold return upgrad share overweight sever reason
new platform launch address concern senza
differenti versu multi-mod system lead market
share gain
competit commerci disrupt risk number sentiment
understood
catalyst path begin robust includ
nsbp
risk execut new strateg vision remain pend
yesterday action materi step address lack recent valu
new begin sale execut set inflect key element prior
thesi hf therapi produc differenti result
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
come late offer multipl option beyond hf includ burst
tonic variou novel waveform join player market
shift multipl modal offer earli dilig nan suggest
new platform flexibl remov key barrier adopt
subsequ dilig recent day increas convict like
lead share gain especi given market recept new platform
launch past abbott burst boston wavewrit
intelli rais revenu estim
street repres y/i growth driven us
growth bp us share captur driven market share gain follow
new platform launch ex-u growth compani anniversari
australia reimburs headwind year
competit better understood incumb respons upstart
competit see nan recap well understood investor
larg player anniversari key product launch without major
catalyst next month think still take share
face upstart competit smaller entrant given offer
complet product suit physician certain upstart focu
uniqu waveform deliveri dilig broadli support view
platform reson clinician privat competitor like face
obstacl adopt includ commerci infrastructur clinic trial
product breadth platform begin look similar see
indic expans next frontier lead pdn
nsbp discuss broadli think effect execut
competit
jump catalyst void still commerci disrupt
limit catalyst next month follow sever dataset
nan longer see overhang share think investor
enthusiasm around senza-pdn pain diabet neuropathi senza-nsrbp
non surgic back pain build get closer readout
materi lead competit market
boston push pdn non-surg back clinic trial affirm
fast follow market expans next frontier
competit year behind continu see pdn non-surg
back tam think enthusiasm initi pick
guidanc still open question prize
appoint mr grossman ceo suspend guidanc
previous discuss see prudent cautionari
prior y/i growth guidanc broadli consid
conserv transit may disrupt busi
suggest updat guidanc may lower think well
understood investor focu shift improv
rapidli maintain guidanc would materi posit share think
investor enthusiasm around acceler like overshadow potenti
guidanc reduct investor understand transit year
compani confid new ceo keith grossman given track
record execut abl stabil commerci infrastructur
capit new product launch drive acceler
upgrad overweight pt platform launch manag
chang repres new begin compani materi chang
strategi expect acceler growth share gain next year
competit risk understood risk competitor clinic data
play move think estim rise
enthusiasm around expans increas drive re-rat share
upgrad share overweight model move
materi near term increas estim
growth higher growth warrant higher multipl
price target move sale still discount versu peer
risk upgrad risk thesi includ sale
perform commerci execut could materi disappoint upstart
competitor could acquir and/or obtain fund launch take materi
share market growth slow new platform launch fail
catalyz sale market appetit pre-profit smid wane
lead multipl contract
insid detail view key invest point
price target reflect sale estim
median valuat low growth high growth smid
materi share gain expans market growth near term
acceler innov new indic progress faster
timelin expect combin better expect share gain
drive sale acceler high teen lead substanti
re-rat multipl
inflect headwind new platform late
launch lead materi acceler share gain grow
mid-teen expans initi drive market growth enthusiasm
near data readout
growth slow competit headwind less differenti new
platform launch fail catalyz sale less differenti combin
upstart competit execut issu lead growth mid singl digit
lead multipl contract
believ new platform launch
late catalyz acceler share
gain
competit risk clinic
product perspect well understood
clinic data expand key
data pain diabet neuropathi non-
surgic back come
pt ww share increas
revenu
pt us share increas
revenu
pt us market growth assum
pro rata share increas revenu
competit launch data on-going
risk achiev price
and/or new platform launch fail
upstart competitor could acquir
and/or obtain fund launch take
thesi chang last juli downgrad given slower commerci
traction clinic catalyst void less differenti vs competit
dilig continu indic senza high-frequ hf therapi drive
less differenti result impli landmark senza-rct studi year
ago new platform disclos nan manag chang announc
yesterday repres materi chang strategi evid board
commit execut sharehold return upgrad share
overweight sever reason
new platform launch address concern senza
differenti versu multi-mod system lead market share
gain
competit risk number sentiment well understood
catalyst path begin robust includ multipl total
address market expand opportun pdn nsbp
risk execut new strateg vision remain pend
yesterday action materi step address lack recent valu creation
upgrad overweight pt platform launch manag chang
repres new begin compani materi chang strategi
expect acceler growth share gain next year competit risk
understood risk competitor clinic data play move
think estim like rise enthusiasm around expans
increas drive re-rat share upgrad share overweight
model move materi near term increas
estim growth higher growth warrant higher multipl
price target move sale still modest discount
new platform launch lead share gain
new platform launch repres chang strategi last year
market shift multipl modal offer intelli
evolv workflow boston wavewrit platform remain steadfast
market hf senza given clinic superior label howev earlier
year announc new platform launch late offer multipl
option beyond high-frequ hf therapi includ burst tonic variou
novel waveform materi chang strategi still pitch
senza hf product first avail waveform includ novel one
effect offer broadest set modal waveform space
dilig suggest new platform launch well-receiv physician
earli dilig nan suggest could welcom chang physician
provid flexibl remov key barrier adopt
subsequ dilig increas convict chang could lead share
gain market shift multipl modal treatment one prior
impedi physician adopt per dilig perceiv
limit treatment option senza offer
major player new platform launch time-frame
histor new product launch catalyz above-market growth share gain
space launch abbott burst boston wavewrit
intelli approv launch given hurrican issu
abbott experienc slowdown sale start boston
expect take share expect begin see
momentum deceler later year market anniversari digest
product launch effect new platform launch major
player late base latest commun timelin given
new platform featur market prior recept new product launch
think lead acceler sale share gain
platform launch lead share gain given nevro platform launch
absenc new product launch major player rais
revenu estim street repres ww growth
us growth market growth repres bp us
share captur repres substanti us acceler ww growth
growth view upstart risk manag discuss
pleas see exhibit market model
competit better understood growth inflect usher numer
wireless deliveri gener approach expect least two new entrant
next twelv month would surpris see combin
independ path well consolid exist player and/or devic
compani tangenti interest key compani focu biotronik nalu
saluda stimwav privat cover
pleas see nan recap detail discuss clinic data product
biotronik littl known biotronik platform time prior histori
suggest commerci strategi could center price
nalu nalu develop wireless system novel puls stimul
pattern psp waveform addit data like come may follow
potenti fda approv later year
saluda evok data show superior back pain non-inferior
posit trend leg pain view efficaci strong still expect
posit longer term evok data may follow eu approv later
year us approv think saluda efficaci well understood
investor rather question saluda necessari fund
launch larg enough salesforc take share whether medtron
choos take larger stake/partnership saluda remain open question
knowledg potenti transact
stimwav stimwav expect launch wireless system hf burst
compani traction expect think question
technolog reimburs dynam initi impedi
share captur note file lawsuit stimwav await updat
litig launch strategi
competit better understood incumb respons upstart competit
well understood investor larg player anniversari key product
launch without major catalyst next month think
still take share face upstart competit smaller entrant describ
given offer complet product suit physician
certain upstart focu uniqu waveform deliveri dilig broadli
support view platform reson clinician privat competitor
could like face obstacl adopt includ commerci infrastructur clinic trial
product breadth platform begin look similar see indic
expans next frontier lead pdn nsbp broadli
think effect execut competit
jump catalyst void
view clinic catalyst chang competitor dataset
understood prior downgrad discuss key clinic catalyst senza-pdn
senza-nsrbp come lead clinic catalyst void year
head competitor dataset still clinic catalyst void still
year follow sever dataset nan longer see overhang
share think investor enthusiasm around senza-pdn pain diabet
neuropathi senza-nsrbp non surgic back pain build get
closer readout materi lead competit
market boston push pdn non-surg back clinic trial
affirm fast follow market expans next frontier
competit least year behind continu see pdn non-
surgic back tam think enthusiasm initi pick
thought
guidanc still open question prize appoint
mr grossman ceo suspend guidanc previous discuss
see prudent cautionari prior y/i
growth guidanc broadli consid conserv transit may
disrupt busi suggest updat guidanc may lower think
well understood investor focu shift improv
rapidli maintain guidanc would materi posit share think
investor enthusiasm around acceler overshadow potenti guidanc
reduct investor understand transit year compani
still face headwind discuss follow result still like
face headwind includ question market growth
key catalyst salesforc hire product issu
hire shortfal australia reimburs pressur estim could pt
bp headwind ex-u ww growth respect potenti
disrupt leadership transit commerci organ specif
market requir activ clinician detail support
drive acceler confid new ceo keith grossman given
track record execut abl stabil commerci infrastructur
capit new product launch drive acceler rais
revenu estim street repres y/i
growth driven us growth bp us share captur driven
market share gain follow new platform launch ex-u growth
compani anniversari australia reimburs headwind year
model acceler platform launch re-evalu model
rais revenu estim consensu
repres y/i growth expect platform launch execut
acceler sale drive share gain us see growth acceler
expect outgrow market growth rate take bp us
share intern busi think anniversari low-singl digit
declin year australia reimburs headwind could lead growth
think investor understand transit year compani
expect enthusiasm around acceler drive share later year
confid new ceo keith grossman given track record execut
abl stabil commerci infrastructur capit new product launch
drive acceler
higher revenu multipl move pt higher growth warrant higher
multipl price target move sale high-growth smid
med-tech growth current trade ev/sal slower growth smid
med-tech growth current trade ev/sal think growth
profil next year warrant valuat two think ev/sal multipl
appropri
bear bull case bear case valuat similar prior
base case reflect sale bear case revenu estim
reflect mid-singl digit growth continu prior
guidanc trend new platform launch strategi fail acceler market
growth bull case valuat high-teen top-line growth drive
sale estim warrant higher multipl ev/sal still
repres discount high-growth smid med-tech
risk upgrad risk thesi includ sale
perform commerci execut could materi disappoint upstart
competitor could acquir and/or obtain fund launch take materi share
market growth slow new platform launch fail catalyz sale
market appetit pre-profit smid wane lead multipl
morgan stanley research thomson reuter non-cov valuat base consensu estim
morgan stanley research thomson reuter non-cov valuat base consensu estim
accret redeem convert prefer stock redempt valu
dollar million except per share data
good sold
dollar million except per share data
dollar million except per share data
accumul comprehens loss
dollar million except per share data
non-cash loss extinguish debt
payment origin issu discount
provis doubt account
write-down inventori
unreal loss foreign currenc transact
purchas short-term invest
proce matur short-term invest
chang restrict cash
proce issuanc common stock underwritten public offer
proce issuanc convert note
convert note initi issuanc discount debt issuanc cost
proce issuanc warrant
purchas convert note hedg
repay debt
purchas common stock proce issuanc common stock stock option exercis
begin period
end period
million
